Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06951984

Hydroxyephedrine PET/CT in Sympathetic Nervous System Disease

Hydroxyephedrine PET/CT in Sympathetic Nervous System Diseases

Status
Recruiting
Phase
Study type
Observational
Enrollment
500 (estimated)
Sponsor
Tianjin Medical University · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Accepted

Summary

To evaluate the potential usefulness of 11C/18F-HED positron emission tomography/ computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various Tau-related disease patients.

Detailed description

Subjects with various sympathetic nerves-related disease patients underwent 11C/18F-HED PET/CT either for an initial assessment or for recurrence detection. Lesions uptake was quantified by the maximum standard uptake value (SUVmax). The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of 11C/18F-HED PET/CT were calculated.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TEST11C/18F-HEDEach subject receive a single intravenous injection of 11C/18F-HED and undergo PET/CT or MRI imaging within the specificed time.

Timeline

Start date
2013-03-01
Primary completion
2028-03-01
Completion
2028-03-01
First posted
2025-04-30
Last updated
2025-04-30

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06951984. Inclusion in this directory is not an endorsement.